Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. 2003 Sep; 62(9): 795–798.
PMCID: PMC1754664

Lupus nephritis: current issues

Full Text

The Full Text of this article is available as a PDF (63K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Oelke Kurt, Richardson Bruce. Pathogenesis of lupus. Arthritis Rheum. 2002 Jun 15;47(3):343–345. [PubMed]
  • Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus. 1993 Oct;2(5):303–312. [PubMed]
  • Wallace DJ, Podell TE, Weiner JM, Cox MB, Klinenberg JR, Forouzesh S, Dubois EL. Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med. 1982 Feb;72(2):209–220. [PubMed]
  • Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Doménech I, Aydintug AO, Jedryka-Góral A, de Ramón E, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993 Mar;72(2):113–124. [PubMed]
  • Nossent HC, Henzen-Logmans SC, Vroom TM, Berden JH, Swaak TJ. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum. 1990 Jul;33(7):970–977. [PubMed]
  • Seligman Victoria A, Lum Raymond F, Olson Jean L, Li Hongzhe, Criswell Lindsey A. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med. 2002 Jun 15;112(9):726–729. [PubMed]
  • Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000 May;35(5):904–914. [PubMed]
  • Huong DL, Papo T, Beaufils H, Wechsler B, Blétry O, Baumelou A, Godeau P, Piette JC. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 1999 May;78(3):148–166. [PubMed]
  • Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997 Apr;51(4):1188–1195. [PubMed]
  • Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MG, Kimberly RP. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest. 1996 Mar 1;97(5):1348–1354. [PMC free article] [PubMed]
  • Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999 Jul;42(7):1309–1311. [PubMed]
  • Cervera Ricard, Piette Jean-Charles, Font Josep, Khamashta Munther A, Shoenfeld Yehuda, Camps María Teresa, Jacobsen Soren, Lakos Gabriella, Tincani Angela, Kontopoulou-Griva Irene, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019–1027. [PubMed]
  • Tektonidou MG, Ioannidis JP, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM. 2000 Aug;93(8):523–530. [PubMed]
  • Nzerue Chike M, Hewan-Lowe Karlene, Pierangeli Silvia, Harris E Nigel. "Black swan in the kidney": renal involvement in the antiphospholipid antibody syndrome. Kidney Int. 2002 Sep;62(3):733–744. [PubMed]
  • Vlachoyiannopoulos PG, Kanellopoulos P, Tektonidou M, Moutsopoulos HM. Renal involvement in antiphospholipid syndrome. Nephrol Dial Transplant. 2001;16 (Suppl 6):60–62. [PubMed]
  • Moss KE, Isenberg DA. Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone. Rheumatology (Oxford) 2001 Aug;40(8):863–867. [PubMed]
  • Daugas Eric, Nochy Dominique, Huong Du Le Thi, Duhaut Pierre, Beaufils Hélène, Caudwell Valérie, Bariety Jean, Piette Jean-Charles, Hill Gary. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol. 2002 Jan;13(1):42–52. [PubMed]
  • Karim MY, Alba P, Tungekar MF, Abbs IC, Khamashta MA, Hughes GRV, Hunt BJ. Hypertension as the presenting feature of the antiphospholipid syndrome. Lupus. 2002;11(4):253–256. [PubMed]
  • Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 Aug 21;135(4):248–257. [PubMed]
  • Austin HA, 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986 Mar 6;314(10):614–619. [PubMed]
  • Ortmann RA, Klippel JH. Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am. 2000 May;26(2):363–vii. [PubMed]
  • Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, Moutsopoulos HM. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000 Jan;57(1):258–264. [PubMed]
  • Boumpas DT, Austin HA, 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993 Sep 1;119(5):366–369. [PubMed]
  • Ioannidis John P A, Katsifis Gikas E, Tzioufas Athanasios G, Moutsopoulos Haralampos M. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol. 2002 Oct;29(10):2129–2135. [PubMed]
  • Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Ioannidis JPA. Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2002 Jul;41(7):780–786. [PubMed]
  • Houssiau Frédéric A, Vasconcelos Carlos, D'Cruz David, Sebastiani Gian Domenico, Garrido Ed Enrique de Ramon, Danieli Maria Giovanna, Abramovicz Daniel, Blockmans Daniel, Mathieu Alessandro, Direskeneli Haner, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002 Aug;46(8):2121–2131. [PubMed]
  • Kolasinski Sharon L, Chung James B, Albert Daniel A. What do we know about lupus membranous nephropathy? An analytic review. Arthritis Rheum. 2002 Aug;47(4):450–455. [PubMed]
  • Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999 Aug 14;354(9178):569–570. [PubMed]
  • Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000 Oct 19;343(16):1156–1162. [PubMed]
  • Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997 Oct 1;159(7):3104–3108. [PubMed]
  • Boumpas Dimitrios T, Furie Richard, Manzi Susan, Illei Gabor G, Wallace Daniel J, Balow James E, Vaishnaw Akshay. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003 Mar;48(3):719–727. [PubMed]
  • Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, Dang CV, Brodsky I, Jones RJ. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med. 1998 Dec 15;129(12):1031–1035. [PubMed]
  • Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet. 2000 Aug 26;356(9231):701–707. [PubMed]
  • Traynor Ann E, Barr Walter G, Rosa Robert M, Rodriguez Julianne, Oyama Yu, Baker Steven, Brush Mary, Burt Richard K. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum. 2002 Nov;46(11):2917–2923. [PubMed]
  • Gescuk Bryan D, Davis John C., Jr Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol. 2002 Sep;14(5):515–521. [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...